Carrier Molecule Compositions and Related Methods

Abstract

A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one hydrophobic domain and where the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.

What is claimed is: 
     
         1 . A composition comprising:
 a carrier molecule comprising at least one cell penetrating peptide (CPP), the carrier molecule comprising at least one hydrophobic domain;   wherein the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.   
     
     
         2 . The composition of  claim 1 , wherein the carrier molecule is amphiphilic. 
     
     
         3 . The composition of  claim 1 , wherein the carrier molecule comprises at least one carbohydrate moiety. 
     
     
         4 . The composition of  claim 1 , wherein the carrier molecule comprises at least one alkyl chain. 
     
     
         5 . The composition of  claim 1 , wherein the carrier molecule comprises at least three hydrophobic amino acids. 
     
     
         6 . The composition of  claim 1 , wherein the carrier molecule comprises at least one phenylalanine. 
     
     
         7 . The composition of  claim 1 , wherein the carrier molecule comprises one of palmitoyl-gly p -KKRPKPG (SEQ ID NO: 5), octanoyl-gly p -KKRPKPG (SEQ ID NO: 6), oleyl-gly p -KKRPKPG (SEQ ID NO: 7) and any combination thereof, where p is an integer from 0 to 20. 
     
     
         8 . The composition of  claim 1 , wherein the carrier molecule is selected from the group consisting of FFFILVF-gly p -KKRPKPG (SEQ ID NO: 1), FLVFFF-gly p -KKRPKPG (SEQ ID NO: 2), KKRPKPG-gly p -FLVFFF (SEQ ID NO: 3), and any combination thereof, where p is an integer from 0 to 10. 
     
     
         9 . The composition of  claim 1 , wherein the at least one CPP is selected from the group consisting of: an HIV-TAT fragment selected from the group consisting of a fragment that has the formula (gly) p -RGRDDRRQRRR-(gly) q  (SEQ ID NO: 8), a fragment that has the formula (gly) p -YGRKKRRQRRR-(gly) q  (SEQ ID NO: 9), a fragment that has the formula (gly) p -RKKRRQRRR-(gly) q  (SEQ ID NO: 10), wherein the subscripts p and q are each independently an integer from 0 to 20; KKRPKPG (SEQ ID NO: 17); AAVLLPVLLAAP (SEQ ID NO: 15), and any combination thereof. 
     
     
         10 . The composition of  claim 1 , wherein the biologically active molecule is selected from the group consisting of VGVAPG (SEQ ID NO: 26); palmitoyl-TTS; retinyl retinoate; retinoic acid; steroid and steroidal compounds; hydroquinone; hyalonuric acid; non-steroidal anti-inflammatory drugs (NSAIDs) including naproxen, ibuprofen, and acetaminophen; skin-tightening peptides; light activatable moieties and compounds; ultraviolet (UV) light absorbing, blocking, or reflecting compounds; vitamins; cholesterol; drugs which block, influence, or interfere with neurotransmitter (such as acetylcholine) function; and any combination thereof. 
     
     
         11 . The composition of  claim 1 , wherein the biologically active molecule is selected from the group consisting of: a  botulinum  toxin serotype selected from the group consisting of A, B, C, D, E, F, and G; recombinant  botulinum  toxin; a modified  botulinum  toxin; a fragment of a  botulinum  toxin; and any combination thereof. 
     
     
         12 . A composition comprising:
 a biologically active molecule; and   a carrier molecule comprising at least one lipophilic domain and at least one cell penetrating peptide (CPP), the carrier molecule further comprising one of:
 at least one carbohydrate moiety; 
 at least one alkyl chain; 
 at least three hydrophobic amino acids; and 
 any combination thereof; and 
   wherein the carrier molecule and biologically active molecule associate non-covalently.   
     
     
         13 . The composition of  claim 12 , wherein the carrier molecule comprises one of palmitoyl-gly p -KKRPKPG (SEQ ID NO: 5), octanoyl-gly p -KKRPKPG (SEQ ID NO: 6), oleyl-gly p -KKRPKPG (SEQ ID NO: 7) and any combination thereof, where p is an integer from 0 to 20. 
     
     
         14 . The composition of  claim 12 , wherein the carrier molecule is selected from the group consisting of FFFILVF-gly p -KKRPKPG (SEQ ID NO: 1), FLVFFF-gly p -KKRPKPG (SEQ ID NO: 2), KKRPKPG-gly p -FLVFFF (SEQ ID NO: 3), and any combination thereof, where p is an integer from 0 to 10. 
     
     
         15 . The composition of  claim 12 , wherein the at least one CPP is selected from the group consisting of: an HIV-TAT fragment selected from the group consisting of a fragment that has the formula (gly) p -RGRDDRRQRRR-(gly) q  (SEQ ID NO: 8), a fragment that has the formula (gly) p -YGRKKRRQRRR-(gly) q  (SEQ ID NO: 9), a fragment that has the formula (gly) p -RKKRRQRRR-(gly) q  (SEQ ID NO: 10), wherein the subscripts p and q are each independently an integer from 0 to 20; KKRPKPG (SEQ ID NO: 17); AAVLLPVLLAAP (SEQ ID NO: 15), and any combination thereof. 
     
     
         16 . The composition of  claim 12 , wherein the biologically active molecule is selected from the group consisting of VGVAPG (SEQ ID NO: 26); palmitoyl-TTS; retinyl retinoate; retinoic acid; steroid and steroidal compounds; hydroquinone; hyalonuric acid; non-steroidal anti-inflammatory drugs (NSAIDs) including naproxen, ibuprofen, and acetaminophen; skin-tightening peptides; light activatable moieties and compounds; ultraviolet (UV) light absorbing, blocking, or reflecting compounds; vitamins; cholesterol; drugs which block, influence, or interfere with neurotransmitter (such as acetylcholine) function; and any combination thereof. 
     
     
         17 . The composition of  claim 12 , wherein the biologically active molecule is selected from the group consisting of: a  botulinum  toxin serotype selected from the group consisting of A, B, C, D, E, F, and G; recombinant  botulinum  toxin; a modified  botulinum  toxin; a fragment of a  botulinum  toxin; and any combination thereof. 
     
     
         18 . A kit for administration of a  botulinum  toxin to a patient, the kit comprising:
 a  botulinum  toxin;   an effective amount for transdermal delivery thereof of a carrier molecule comprising at least one cell penetrating peptide (CPP), the carrier molecule comprising at least one hydrophobic domain;   a pH buffer system adapted to maintain pH between 4.0 to 8.3; and   a device comprising the  botulinum  toxin, the carrier molecule, and the pH buffer system, the device adapted to administer the  botulinum  toxin to a patient via the patient's skin;   wherein the carrier molecule is non-covalently associated with the  botulinum  toxin in one of a micelle and a liposome; and   wherein one of the device, the carrier molecule, the pH buffer system, and any combination thereof are adapted to provide a controlled release of the  botulinum  toxin.   
     
     
         19 . The kit of  claim 18 , wherein the device is a skin patch. 
     
     
         20 . The kit of  claim 18 , wherein the  botulinum  toxin, the carrier molecule, and the pH buffer system are comprised in a liquid, gel, cream, lotion, and ointment coupled with the device.